We use cookies for a better user experience. Read our Privacy Policy

I Agree

Tamiflu (Oseltamivir Phosphate) Market

Tamiflu (Oseltamivir Phosphate) Market (Drug Type: Branded and Generic; Dosage Form: Capsule and Suspension; Indication: Influenza A, Influenza B, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

OTC Distribution Drives Tamiflu (Oseltamivir Phosphate) Market

High prevalence of influenza and flu has created a demand for Tamiflu (Oseltamivir Phosphate). Thus, companies are entering into strategic deals to gain rights for over-the-counter (OTC) distribution of the medication. For instance, in July 2019, leading French multinational pharmaceutical company Sanofi entered into an agreement with Roche-a Swiss multinational healthcare company, to gain rights for over-the-counter distribution of Tamiflu in the U.S. Such deals are boosting the growth of the Tamiflu (Oseltamivir Phosphate) market, which is projected to reach a revenue of ~US$ 940 Mn by the end of 2027.

Companies in the Tamiflu (Oseltamivir Phosphate) market are increasing their production capabilities to manufacture novel medication for the prevention and treatment of life-threatening influenza diseases and other flu. They are increasing efficacy in FDA negotiations for marketing and scientific engagement associated with Tamiflu to gain credibility in the global market landscape.

tamiflu market infographic

To know the scope of our report Get a Sample on Tamiflu (Oseltamivir Phosphate) Market

Popularity of OTC Distribution in U.S. Catches Attention of Leading Healthcare Companies

The Tamiflu (Oseltamivir Phosphate) market is witnessing change, since healthcare companies are pervasively switching toward OTC distribution, especially in the U.S. Since the U.S. being one of the rapidly growing economies of North America, the latter is expected to reach the second-highest revenue in the Tamiflu (Oseltamivir Phosphate) market by the end of 2027. Hence, companies in the U.S. are capitalizing on the trend of OTC switch. Looking at leading market players, even emerging players are aiming at the OTC switch and aiming toward strategic transactions to introduce innovations in Tamiflu (Oseltamivir Phosphate).

Companies in the market for Tamiflu (Oseltamivir Phosphate) are targeting the U.S., since the region is one of the largest OTC market worldwide. The OTC switch is supporting the global cough and cold strategy of market players by expanding into flu with a sustainable point of difference in the market. Tamiflu is being highly publicized in support of public health, since novel medication offers safe and efficacious treatment for flu and influenza.

Companies Target Patients with Renal Diseases to Grow in Global Market

Health institutions such as the Centers for Disease Control and Prevention, U.S., recommend that newly born infants should receive flu vaccine at regular periodic intervals. However, frequent replication and mutation of the influenza virus has contributed toward high prevalence of the infection. This phenomena has fueled the demand for Tamiflu (Oseltamivir Phosphate) medication. However, substitute antiviral drugs such as Baloxavir marboxil and Peramivir pose as a threat to the sales of Tamiflu (Oseltamivir Phosphate). Easy availability of substitute drugs explains the steep downward Y-o-Y growth of the Tamiflu (Oseltamivir Phosphate) market. Hence, manufacturers are entering into strategic deals for OTC distribution and increasing production capabilities in dosage forms of Tamiflu.

Get a glimpse of the in-depth analysis through our Report Brochure

Tamiflu capsules dictate the highest revenue as compared to suspension dosages in the Tamiflu (Oseltamivir Phosphate) market and the capsule dosage form segment is predicted for exponential growth in the coming years. On the other hand, companies are increasing the availability of Tamiflu in the suspension dosage form for patients with end-stage renal disease (ESRD) and those on continuous ambulatory peritoneal dialysis (CAPD).

Publicly Funded Research Studies in Europe Offer Strategic Insights to Healthcare Companies

It has been found that Tamiflu (Oseltamivir Phosphate) is an efficacious antiviral drug for the treatment of flu and influenza, especially among the geriatric patients. Companies in the Tamiflu (Oseltamivir Phosphate) market are increasing their focus in Europe, this market in the region is expected for aggressive growth during the forecast period. The Lancet- a European Commission-funded study revealed that Tamiflu (Oseltamivir Phosphate) is recommended by public health agencies for the prevention and treatment of seasonal and pandemic influenza outbreaks.

Ongoing research studies that are publicly funded in several European countries are generating incremental opportunities for companies in the Tamiflu (Oseltamivir Phosphate) market, since companies are gaining important insights through these studies. Healthcare providers in Europe are also recommending Tamiflu for young and old patients with flu-like illnesses.

tamiflu market segmentation
Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

Healthcare companies in the Tamiflu (Oseltamivir Phosphate) market are exploring opportunities in Asia Pacific, since government institutions in the region are increasing their efforts to improve the healthcare infrastructure. On the other hand, companies are maximizing their production capabilities to develop generic drugs and increasing efforts to strengthen their online distribution channels.

Tamiflu is efficacious in the treatment of ESRD and for patients who rely on CAPD. However, side effects of Tamiflu, such as diarrhea, and introduction of substitute drugs such as XofluzaTM (baloxavir marboxil) by Roche, are likely to slow down market growth. Hence, companies should increase their efficacy in conducting extensive research studies catering to the development of drugs targeting children and infants.

Tamiflu (Oseltamivir Phosphate) Market: Overview

  • Tamiflu (Oseltamivir Phosphate) is a medicine under the class of neuraminidase inhibitor used as an antiviral agent
  • This drug is widely used for the treatment of symptoms caused by the flu virus (Influenza). Tamiflu is a brand name, while oseltamivir phosphate is a generic name for the same. It is available in capsule and oral suspension dosage forms.
  • Seasonal outbreak of influenza primarily occurs in winter. Most people generally recover fully, but severe complications such as pneumonia can also develop. Initiation of antiviral treatment is recommended for hospitalized influenza patients.
  • Tamiflu is prescribed for the treatment of acute, and uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. It is also given for prophylactic use as prophylaxis of influenza A and B in patients 1 year and older.
  • Prevention of flu includes avoiding unnecessary close contact between sick and healthy people, covering mouth and nose while coughing & sneezing, and washing hands frequently
  • High prevalence, rise in patient population affected by influenza, and pandemic influenza outbreak are some of the major factors responsible for the growth of global Tamiflu (Oseltamivir Phosphate) market
  • For instance, according to the Centers for Disease Control and Prevention (CDC), around 5% to 20% of the population is affected by the flu in the U.S. each year. Additionally, an estimated 200,000 people are hospitalized due to flu infection in the U.S. each year; of these 36,000 die due to flu complications.
  • Increase in initiatives by regulatory authorities & organizations for treatment and prevention of influenza is also contributing for the growth of the global Tamiflu (Oseltamivir Phosphate) market
  • Moreover, surge in government funding and measures for influenza treatment & prevention in terms of research activities and awareness campaigns is responsible for the growth of Tamiflu (Oseltamivir Phosphate) market

Market Segmentation: Tamiflu (Oseltamivir Phosphate) Market

  • Based on drug type, the global Tamiflu (Oseltamivir Phosphate) market has been classified into branded and generic
  • The generic segment dominated the global Tamiflu (Oseltamivir Phosphate) market in 2018 and its share in global market in increasing
  • Patent expiry of branded Tamiflu in 2016, several generic products launches, and cheaper products are some of the major factors driving the generic segment
  • In terms of dosage form, the global Tamiflu (Oseltamivir Phosphate) market has been bifurcated into capsule and suspension
  • On the basis of Indication, the global market has been segmented into influenza A, influenza B, and others
  • Based on distribution channel, the global Tamiflu (Oseltamivir Phosphate) market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and others
  • Each of the segments has been analyzed in detail for market trends, recent trends and developments, drivers, restraints, opportunities, and useful insights
  • The report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027, along with market size estimations.

Regional Overview: Tamiflu (Oseltamivir Phosphate) Market

  • In terms of region, the global Tamiflu (Oseltamivir Phosphate) market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.
  • North America accounted for major share of the global Tamiflu (Oseltamivir Phosphate) market in 2018. Higher prevalence of influenza, presence of major companies in the region, and better influenza surveillance for reporting on weekly basis are some of the major factors responsible for the growth of North America Tamiflu (Oseltamivir Phosphate) market.
  • The current and future market sizes in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGRs for the period from 2019 to 2027
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which will help new companies willing to enter the market and existing companies to increase market shares, and help in the decision-making process

Major Players

  • The report concludes with company profiles section that includes key information about the major players in the market
  • Key players analyzed in this report are
    • F.Hoffmann-La Roche Ltd.
    • NATCO Pharma Limited
    • Tea Pharmaceutical Industries Ltd.
    • LUPIN Limited
    • Amneal Pharmaceuticals LLC
    • Zydus Cadila
    • Sun Pharmaceutical Industries Ltd.
    • Alembic Pharmaceuticals Limited
    • Mylan N.V.
    • Hetero Group
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Tamiflu (Oseltamivir Phosphate) Market – Segmentation

TMR’s study on the global Tamiflu (Oseltamivir Phosphate) market includes information divided into five sections-drug type, dosage form, indication, distribution channel, and by region. Changing industry trends and other crucial market dynamics associated with these sections of the global Tamiflu (Oseltamivir Phosphate) market have been discussed in detail.

Drug Type

Branded

Generic

Dosage Form

Capsule

Suspension

Indication

Influenza A

Influenza B

Others

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Tamiflu (Oseltamivir Phosphate) Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of tamiflu (oseltamivir phosphate) market?

Tamiflu (oseltamivir phosphate) market is projected to reach a revenue of ~US$ 940 Mn by the end of 2027

What is the anticipated CAGR of the tamiflu (oseltamivir phosphate) market in the forecast period?

Tamiflu (oseltamivir phosphate) market is expected to expand at a CAGR of -4% during the forecast period from 2019 to 2027

What are the key driving factors for the growth of the tamiflu (oseltamivir phosphate) market?

Tamiflu (oseltamivir phosphate) market is driven by increase in prevalence of influenza across the globe

Which region is expected to project the highest market share in the global tamiflu (oseltamivir phosphate) market?

North America accounted for a major share of the global tamiflu (oseltamivir phosphate) market

Who are the key players in the tamiflu (oseltamivir phosphate) market?

Key players in the tamiflu (oseltamivir phosphate) market include F.Hoffmann-La Roche Ltd., NATCO Pharma Limited, Tea Pharmaceutical Industries Ltd., LUPIN Limited, Amneal Pharmaceuticals LLC

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Tamiflu (Oseltamivir Phosphate) Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

    5.1. 5.1.Influenza Flu Prevalence globally

    5.2. 5.2.Key Mergers, Acquisition, and Strategic Partnerships 

    5.3. 5.3.Top Dugs Sales Analysis of Oseltamivir Phosphate brand

6. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, by Drug Type 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Type, 2017–2027

        6.3.1. Branded

        6.3.2. Generic

    6.4. Market Attractiveness, by Drug Type 

7. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, by Dosage Form 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Dosage Form, 2017–2027

        7.3.1. Capsule

        7.3.2. Suspension

    7.4. Market Attractiveness, by Dosage Form 

8. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, by Indication 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Indication, 2017–2027

        8.3.1. Influenza A

        8.3.2. Influenza B

        8.3.3. Others

    8.4. Market Attractiveness, by Indication 

9. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, by Distribution Channel 

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Distribution Channel, 2017–2027

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

        9.3.4. Others

    9.4. Market Attractiveness, by Distribution Channel 

10. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America 

        10.2.2. Europe 

        10.2.3. Asia Pacific 

        10.2.4. Latin America 

        10.2.5. Middle East & Africa 

    10.3. Market Attractiveness, by Country/Region

11. North America Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Type, 2017–2027

        11.2.1. Branded

        11.2.2. Generic

    11.3. Market Value Forecast, by Dosage Form, 2017–2027

        11.3.1. Capsule

        11.3.2. Suspension

    11.4. Market Value Forecast, by Indication, 2017–2027

        11.4.1. Influenza A

        11.4.2. Influenza B

        11.4.3. Others

    11.5. Market Value Forecast, by Distribution Channel, 2017–2027

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Online Pharmacies

        11.5.4. Others

    11.6. Market Value Forecast, by Country, 2017–2027

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis 

        11.7.1. By Drug Type 

        11.7.2. By Dosage Form 

        11.7.3. By Indication 

        11.7.4. By Distribution Channel 

        11.7.5. By Country

12. Europe Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Type, 2017–2027

        12.2.1. Branded

        12.2.2. Generic

    12.3. Market Value Forecast, by Dosage Form, 2017–2027

        12.3.1. Capsule

        12.3.2. Suspension

    12.4. Market Value Forecast, by Indication, 2017–2027

        12.4.1. Influenza A

        12.4.2. Influenza B

        12.4.3. Others

    12.5. Market Value Forecast, by Distribution Channel, 2017–2027

        12.5.1. Hospital Pharmacies

        12.5.2. Retail Pharmacies

        12.5.3. Online Pharmacies

        12.5.4. Others

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2027

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis 

        12.7.1. By Drug Type 

        12.7.2. By Dosage Form 

        12.7.3. By Indication 

        12.7.4. By Distribution Channel 

        12.7.5. By Country/Sub-region

13. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Type, 2017–2027

        13.2.1. Branded

        13.2.2. Generic

    13.3. Market Value Forecast, by Dosage Form, 2017–2027

        13.3.1. Capsule

        13.3.2. Suspension

    13.4. Market Value Forecast, by Indication, 2017–2027

        13.4.1. Influenza A

        13.4.2. Influenza B

        13.4.3. Others

    13.5. Market Value Forecast, by Distribution Channel, 2017–2027

        13.5.1. Hospital Pharmacies

        13.5.2. Retail Pharmacies

        13.5.3. Online Pharmacies

        13.5.4. Others

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2027

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis 

        13.7.1. By Drug Type 

        13.7.2. By Dosage Form 

        13.7.3. By Indication 

        13.7.4. By Distribution Channel 

        13.7.5. By Country/Sub-region

14. Latin America Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Type, 2017–2027

        14.2.1. Branded

        14.2.2. Generic

    14.3. Market Value Forecast, by Dosage Form, 2017–2027

        14.3.1. Capsule

        14.3.2. Suspension

    14.4. Market Value Forecast, by Indication, 2017–2027

        14.4.1. Influenza A

        14.4.2. Influenza B

        14.4.3. Others

    14.5. Market Value Forecast, by Distribution Channel, 2017–2027

        14.5.1. Hospital Pharmacies

        14.5.2. Retail Pharmacies

        14.5.3. Online Pharmacies

        14.5.4. Others

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2027

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis 

        14.7.1. By Drug Type 

        14.7.2. By Dosage Form 

        14.7.3. By Indication 

        14.7.4. By Distribution Channel 

        14.7.5. By Country/Sub-region

15. Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Drug Type, 2017–2027

        15.2.1. Branded

        15.2.2. Generic

    15.3. Market Value Forecast, by Dosage Form, 2017–2027

        15.3.1. Capsule

        15.3.2. Suspension

    15.4. Market Value Forecast, by Indication, 2017–2027

        15.4.1. Influenza A

        15.4.2. Influenza B

        15.4.3. Others

    15.5. Market Value Forecast, by Distribution Channel, 2017–2027

        15.5.1. Hospital Pharmacies

        15.5.2. Retail Pharmacies

        15.5.3. Online Pharmacies

        15.5.4. Others

    15.6. Market Value Forecast, by Country/Sub-region, 2017–2027

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis 

        15.7.1. By Drug Type 

        15.7.2. By Dosage Form 

        15.7.3. By Indication 

        15.7.4. By Distribution Channel 

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player – Competition Matrix (By Tier and Size of companies)

    16.2. Market Share Analysis, by Company (2016)

    16.3. Company Profiles

        16.3.1. F.Hoffmann-La Roche Ltd.

            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.1.2. Company Financials

            16.3.1.3. Growth Strategies

            16.3.1.4. SWOT Analysis

        16.3.2. NATCO Pharma Limited

            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.2.2. Company Financials

            16.3.2.3. Growth Strategies

            16.3.2.4. SWOT Analysis

        16.3.3. Teva Pharmaceutical Industries Ltd.

            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.3.2. Company Financials

            16.3.3.3. Growth Strategies

            16.3.3.4. SWOT Analysis

        16.3.4. LUPIN Limited

            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.4.2. Company Financials

            16.3.4.3. Growth Strategies

            16.3.4.4. SWOT Analysis

        16.3.5. Amneal pharmaceuticals LLC

            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.5.2. Company Financials

            16.3.5.3. Growth Strategies

            16.3.5.4. SWOT Analysis

        16.3.6. Zydus Cadila

            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.6.2. Company Financials

            16.3.6.3. Growth Strategies

            16.3.6.4. SWOT Analysis

        16.3.7. Sun Pharmaceutical Industries Ltd. 

            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.7.2. Company Financials

            16.3.7.3. Growth Strategies

            16.3.7.4. SWOT Analysis

        16.3.8. Alembic Pharmaceuticals Limited

            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.8.2. Company Financials

            16.3.8.3. Growth Strategies

            16.3.8.4. SWOT Analysis

        16.3.9. Mylan N.V.

            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.9.2. Company Financials

            16.3.9.3. Growth Strategies

            16.3.9.4. SWOT Analysis

        16.3.10. Hetero Group

            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.10.2. Company Financials

            16.3.10.3. Growth Strategies

            16.3.10.4. SWOT Analysis

List of Tables

Table 01: Key Mergers, Acquisition, and Strategic Partnerships

Table 02: Top Drugs Sales (US$ Mn) Analysis of Oseltamivir Phosphate brand (Tamiflu) by F.Hoffmann-La Roche Ltd.

Table 03: Global Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 04: Global Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 05: Global Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 06: Global Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 07: Global Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 08: North America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Country, 2017–2027 

Table 09: North America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 10: North America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 11: North America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Indication, 2016–2026

Table 12: North America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027 

Table 13: Europe Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 14: Europe Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 15: Europe Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 16: Europe Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Indication, 2016–2026

Table 17: Europe Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027 

Table 18: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 19: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 20: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 21: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Indication, 2016–2026

Table 22: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027 

Table 23: Latin America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 24: Latin America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 25: Latin America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 26: Latin America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Indication, 2016–2026

Table 27: Latin America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027 

Table 28: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 29: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 30: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 31: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Indication, 2016–2026

Table 32: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

List of Figures

Figure 01: Global Tamiflu (Oseltamivir Phosphate) Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 02: Global Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast, 2017–2027

Figure 03: Global Tamiflu (Oseltamivir Phosphate) Market Value Share, by Drug Type (2018)

Figure 04: Global Tamiflu (Oseltamivir Phosphate) Market Value Share, by Dosage Form (2018)

Figure 05: Global Tamiflu (Oseltamivir Phosphate) Market Value Share, by Indication (2018)

Figure 06: Global Tamiflu (Oseltamivir Phosphate) Market Value Share, by Distribution Channel (2018)

Figure 07: Global Tamiflu (Oseltamivir Phosphate) Market Value Share, by Region (2018)

Figure 08: Global Tamiflu (Oseltamivir Phosphate) Market Value Share Analysis, by Drug Type, 2018 and 2027

Figure 09: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Branded, 2017-2027

Figure 10: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Generic, 2017-2027

Figure 11: Global Tamiflu (Oseltamivir Phosphate) Market Attractiveness Analysis, by Drug Type, 2019-2027

Figure 12: Global Tamiflu (Oseltamivir Phosphate) Market Value Share Analysis, by Dosage Form, 2018 and 2027

Figure 13: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Capsule, 2017–2027

Figure 14: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Suspension, 2017–2027

Figure 15: Global Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Dosage Form, 2019–2027

Figure 16: Global Tamiflu (Oseltamivir Phosphate) Market Value Share Analysis, by Indication, 2018 and 2027

Figure 17: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Influenza A, 2017–2027

Figure 18: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Influenza B, 2017–2027

Figure 19: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 20: Global Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Indication, 2019–2027

Figure 21: Global Tamiflu (Oseltamivir Phosphate) Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 22: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

Figure 23: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

Figure 24: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027

Figure 25: Global Tamiflu (Oseltamivir Phosphate) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 26: Global Tamiflu (Oseltamivir Phosphate) Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 27: Global Tamiflu (Oseltamivir Phosphate) Market Value Share, by Region, 2018 and 2027

Figure 28: Global Tamiflu (Oseltamivir Phosphate) Market Attractiveness Analysis, by Region, 2019–2027

Figure 29: North America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 30: North America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Country, 2018 and 2027

Figure 31: North America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Country, 2019–2027

Figure 32: North America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Drug Type, 2018 and 2027

Figure 33: North America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Drug Type, 2019–2027

Figure 34: North America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Dosage Form, 2018 and 2027

Figure 35: North America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Dosage Form, 2019–2027

Figure 36: North America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Indication, 2018 and 2027

Figure 37: North America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Indication, 2019–2027

Figure 38: North America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Distribution Channel, 2018 and 2027 

Figure 39: North America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Distribution Channel, 2019–2027 

Figure 40: Europe Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 41: Europe Tamiflu (Oseltamivir Phosphate) Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 42: Europe Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 43: Europe Tamiflu (Oseltamivir Phosphate) Market Value Share, by Drug Type, 2018 and 2027

Figure 44: Europe Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Drug Type, 2019–2027

Figure 45: Europe Tamiflu (Oseltamivir Phosphate) Market Value Share, by Dosage Form, 2018 and 2027

Figure 46: Europe Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Dosage Form, 2019–2027

Figure 47: Europe Tamiflu (Oseltamivir Phosphate) Market Value Share, by Indication, 2018 and 2027

Figure 48: Europe Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Indication, 2019–2027

Figure 49: Europe Tamiflu (Oseltamivir Phosphate) Market Value Share, by Distribution Channel, 2018 and 2027 

Figure 50: Europe Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Distribution Channel, 2019–2027 

Figure 51: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 52: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 53: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 54: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value Share, by Drug Type, 2018 and 2027

Figure 55: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Drug Type, 2019–2027

Figure 56: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value Share, by Dosage Form, 2018 and 2027

Figure 57: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Dosage Form, 2019–2027

Figure 58: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value Share, by Indication, 2018 and 2027

Figure 59: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Indication, 2019–2027

Figure 60: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Value Share, by Distribution Channel, 2018 and 2027 

Figure 61: Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Distribution Channel, 2019–2027 

Figure 62: Latin America Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 63: Latin America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 64: Latin America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 65: Latin America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Drug Type, 2018 and 2027

Figure 66: Latin America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Drug Type, 2019–2027

Figure 67: Latin America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Dosage Form, 2018 and 2027

Figure 68: Latin America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Dosage Form, 2019–2027

Figure 69: Latin America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Indication, 2018 and 2027

Figure 70: Latin America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Indication, 2019–2027

Figure 71: Latin America Tamiflu (Oseltamivir Phosphate) Market Value Share, by Distribution Channel, 2018 and 2027 

Figure 72: Latin America Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Distribution Channel, 2019–2027 

Figure 73: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 74: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 75: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 76: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value Share, by Drug Type, 2018 and 2027

Figure 77: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Drug Type, 2019–2027

Figure 78: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value Share, by Dosage Form, 2018 and 2027

Figure 79: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Dosage Form, 2019–2027

Figure 80: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value Share, by Indication, 2018 and 2027

Figure 81: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Indication, 2019–2027

Figure 82: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Value Share, by Distribution Channel, 2018 and 2027 

Figure 83: Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Attractiveness, by Distribution Channel, 2019–2027 

Figure 84: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

573

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved